Research notes: Tips for navigating federal funding from the lab to the internet

houston voices

Every researcher needs a Digital Persistent Identifier.

As a researcher, what is more important to you than a record of your research and scholarship? A Digital Persistent Identifier, or DPI, distinguishes you and your work from that of your peers – and having one will be mandated for those receiving federal funding. Let’s take a deeper look at why this number is so important. We’ll also compare the different platforms— ORCID, Web of Science, Scopus and Google Scholar — so that you can be sure your publications, presentations, peer reviews and even information about who is citing you are being properly stored and accessed.

ORCID

There are many types of profiles and DPIs that can meet your needs, but there’s no silver bullet. Placing your work onto multiple platforms is necessary according to Andrea Malone, Research Visibility and Impact Coordinator at UH Libraries. She cautions researchers to “be realistic about how many identifiers you can maintain.”

The most popular is ORCID, which stands for Open Researcher and Contributor ID. It’s free to set up, and there is no chance of accidentally or on-purpose having multiple ORCID accounts – it’s assigned to you like a social security number and follows you, the researcher. This comes in particularly especially handy for researchers with common names.

An identifier is federally mandated for those receiving governmental funds. It is not specified that ORCID must be that identifier. For example, according to Malone: “a Web of Science profile also assigns an identifier, which would also satisfy the mandate.” But most researchers choose ORCID because it’s publicly available with no access restrictions.

While an ORCID number is free for researchers, there is a subscription fee for an institution to be associated with ORCID. Information will not pre-populate in an ORCID profile and it doesn’t track citation counts – it only shows what you put in. There are, however, linking wizards that allow you to link from Web of Science and Scopus to your ORCID account. If you choose this option, citations will automatically populate in your ORCID profile. It’s up to the researcher to doublecheck to be sure the information has automated, however.

Google Scholar

Google Scholar is a profile, not an identifier, so it does not comply with federal funding requirements. It is free, however, and it pulls from the open web. You can choose to have your list of articles updated automatically, review the updates yourself or manually update your articles at any time. Google Scholar also specifies which articles are open access. A PDF or HTML icon will appear on the righthand side of each citation for one to download articles.

Web of Science Vs. Scopus

Scopus is known for covering more journals and a wider range of metrics to evaluate research impact than Web of Science. Different platforms are a go-to for certain disciplines – for example, Web of Science is usually associated with hard sciences, although investigators in the social sciences and humanities also place their work on this platform from time to time. It’s a good idea to check out which platforms others in your discipline are using for their profiles.

Staying up-to-date

Of course, DPIs don’t work as intended unless researchers keep their profiles current. That means you need to check your profile after every publication and every time you switch to a new institution. Just as you would update your CV, you must update your ORCID or other DPI profile.

One tactic Malone suggests is setting a schedule either biweekly or monthly to check all your profiles. “One thing that’s helpful is that with all of them, you can set up alerts and create an alert as often as you want,” Malone goes on. “At that time, the program will scrawl the content within the source and alert you to anytime any of your publications appear in their database.”

The Big Idea

No one tool can paint a complete picture of all your scholarship. Be strategic and intentional about which platforms you use. Consider your audience, the platforms others in your discipline use and make sure you have an ORCID profile to comply with the federal mandate. But be careful not to sign up for more than you can feasibly maintain and keep current.

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME